Prediagnostic Body Mass Index and Pancreatic Cancer Survival
View/ Open
Author
Yuan, Chen
Bao, Ying
Wu, Chen
Kraft, Peter
Ogino, Shuji
Ng, Kimmie
Qian, Zhi Rong
Rubinson, Douglas A.
Giovannucci, Edward L.
Wolpin, Brian M.
Published Version
https://doi.org/10.1200/JCO.2013.51.7532Metadata
Show full item recordCitation
Yuan, Chen, Ying Bao, Chen Wu, Peter Kraft, Shuji Ogino, Kimmie Ng, Zhi Rong Qian, et al. 2013. “Prediagnostic Body Mass Index and Pancreatic Cancer Survival.” Journal of Clinical Oncology 31 (33): 4229–34. https://doi.org/10.1200/jco.2013.51.7532.Abstract
Purpose Although obesity is associated with increased incidence of pancreatic cancer, studies have not prospectively evaluated prediagnostic body mass index (BMI) and survival.Patients and Methods We analyzed survival by prediagnostic BMI assessed in 1986 among 902 patients from two large prospective cohorts diagnosed from 1988 to 2010. We estimated hazard ratios (HRs) for death using Cox proportional hazards models, with adjustment for age, sex, race/ethnicity, smoking, diagnosis year, and stage. We evaluated the temporal association of BMI with survival by grouping reported BMI by 2-year lag-time intervals before diagnosis.Results The multivariable-adjusted HR for death was 1.53 (95% CI, 1.11 to 2.09) comparing patients with BMI 35 kg/m(2) with those with BMI < 25 kg/m(2) (P trend = .001), which was similar after adjustment for stage. The association of BMI with survival was stronger with longer lag times between reported BMI and cancer diagnosis. Among patients with BMI collected 18 to 20 years before diagnosis, HR for death was 2.31 (95% CI, 1.48 to 3.61; P trend < .001), comparing obese with healthy-weight patients. No statistically significant differences were seen by cohort, smoking status, or stage, although the association was stronger among never-smokers (HR, 1.61; 95% CI, 1.01 to 2.57; P trend = .002) than ever-smokers (HR, 1.36; 95% CI, 0.86 to 2.15; P trend = .63), comparing BMI 35 kg/m(2) with BMI < 25 kg/m(2). Higher prediagnostic BMI was associated with more advanced stage at diagnosis, with 72.5% of obese patients presenting with metastatic disease versus 59.4% of healthy-weight patients (P = .02).Conclusion Higher prediagnostic BMI was associated with statistically significantly decreased survival among patients with pancreatic cancer from two large prospective cohorts.Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAPCitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292533
Collections
- SPH Scholarly Articles [6329]
Contact administrator regarding this item (to report mistakes or request changes)